While "the trend is your friend" when it comes to short-term investing or trading, timing entries into the trend is a key determinant of success. And increasing the odds of success by making sure the sustainability of a trend isn't easy.The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the stock aliv ...

Exhibit 99.2 'VERICEL Advanced Therapies for the Sports Medicine & Severe Burn Care 43RD ANNUAL J.P. MO HEALTHCARE CONFER These and other significant factors are dis in Vericel's Annual Report on Form 10- December 31, 2023, filed with the Se Commission (SEC) on February 29, 202 Report on Form 10-Q for the quarter ende filed with the SEC on November 7, 2024, a the SEC. These forward-looking statement the date hereof and Vericel does not a disclaims any obligation to update any of statements to reflect a chan ...

Full-Year 2024 Total Revenue Growth of 20% and Adjusted EBITDA Growth of Approximately 55% MACI Full-Year 2024 Revenue Growth of 20%, with Fourth Quarter Revenue of $68.2 to $68.7 Million Highest Quarterly MACI Implants, Surgeons, and Biopsies Since Launch and Strong Early MACI Arthro Launch Indicators Record Fourth Quarter Gross Margin of Approximately 77% and Adjusted EBITDA Margin of 39% 2025 Total Revenue Guidance of 20% to 23% Growth Mid-Term Profitability Targets Increased to Gross Margin in the High- ...

CAMBRIDGE, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference at 10:30 a.m. ET (7:30 a.m. PT) on Wednesday, January 15, 2025. A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com. About Vericel Corporation Ver ...

Core Insights - Vericel Corporation (NASDAQ: VCEL) has experienced a stock price increase of approximately 40% in recent months, indicating strong market interest and performance [2]. Company Performance - The company is projected to achieve profitability in the current fiscal year, which is a significant milestone for its financial health [2]. - Vericel is witnessing impressive sales growth, contributing to its positive outlook and investor confidence [2]. Valuation Considerations - Following the recent rise in equity, there are concerns regarding the company's valuations, suggesting that investors should be cautious about potential overvaluation [2].

When it comes to short-term investing or trading, they say "the trend is your friend." And there's no denying that this is the most profitable strategy. But making sure of the sustainability of a trend to profit from it is easier said than done.The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the st ...

Core Insights - MannKind Corporation reported strong revenue growth in Q3 2024, indicating a positive performance for the company [5]. Group 1: Company Overview - The conference call featured key participants including Eric Burns (Vice President of Finance & Investor Relations), Nick Colangelo (Chief Executive Officer), and Joe Mara (Chief Financial Officer) [1][2][3]. - The company emphasized the importance of forward-looking statements and the associated risks and uncertainties [4][5]. Group 2: Financial Performance - The company highlighted its outstanding quarter with significant total revenue growth, showcasing its operational success [5].

Company Performance - Vericel Corporation reported a quarterly loss of $0.02 per share, better than the Zacks Consensus Estimate of a loss of $0.05, and an improvement from a loss of $0.08 per share a year ago, representing an earnings surprise of 60% [1] - The company posted revenues of $57.91 million for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 4.68%, and showing an increase from year-ago revenues of $45.58 million [2] - Over the last four quarters, Vericel has surpassed consensus EPS estimates three times and topped consensus revenue estimates two times [2] Stock Performance - Vericel shares have increased approximately 34.9% since the beginning of the year, outperforming the S&P 500's gain of 24.3% [3] - The current consensus EPS estimate for the coming quarter is $0.33 on revenues of $81.48 million, and for the current fiscal year, it is $0.12 on revenues of $240.74 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Vericel belongs, is currently in the top 36% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that industry performance can significantly impact stock performance [5][8]

Financial Performance - Q3 2024 - Record Q3 total revenue reached $57.9 million[3] - MACI revenue experienced a growth of 19% reaching $44.7 million[3] - Burn Care revenue increased by 66% reaching $13.2 million[3] - Gross margin improved to 72%, a 480 bps increase compared to Q3 2023[3] - Adjusted EBITDA increased by 84% reaching $10.0 million compared to Q3 2023[3] Financial Performance - Year-to-Date (YTD) 2024 - Total net revenue increased by 22% to $161.8 million[4] - MACI net revenue grew by 19% to $129.0 million[4] - Burn Care net revenue increased by 35% to $32.9 million[4] - Adjusted EBITDA growth of 103% to $23.6 million, with a 15% adjusted EBITDA margin, up 580 bps vs prior year[4] Financial Guidance - The company anticipates total revenue between $238 million and $242 million[8] - The company raised guidance to 72% gross margin[9] - The company raised guidance to 22% Adjusted EBITDA Margin[9]

Core Insights - Vericel Corporation reported a total revenue growth of 27% to $57.9 million for the third quarter of 2024, compared to $45.6 million in the same period of 2023 [5][2] - The company achieved a gross margin of 72%, an increase of 480 basis points year-over-year, and a significant adjusted EBITDA growth of 84% to $10.0 million [2][6] - Full-year profitability guidance has been raised, with expectations of a gross margin of 72% and an adjusted EBITDA margin of 22% [5] Financial Highlights - Total net revenue for Q3 2024 was $57.9 million, with MACI® net revenue growing 19% to $44.7 million and Burn Care net revenue increasing 66% to $13.2 million [2][5] - Year-to-date total net revenue increased 22% to $161.8 million, with MACI net revenue growth of 19% to $129.0 million and Burn Care net revenue growth of 35% to $32.9 million [3] - The company reported a net loss of $0.9 million, or $0.02 per diluted share, compared to a net loss of $3.7 million, or $0.08 per diluted share, in Q3 2023 [7][2] Business Developments - Vericel achieved record highs in total revenue, MACI revenue, and Epicel revenue for the third quarter [4] - The FDA approved MACI Arthro™ for repairing symptomatic cartilage defects in the knee, and a pediatric indication for NexoBrid was also approved [4] - The company is on track to submit MACI Ankle™ IND in the first half of 2025 and expects to initiate clinical studies in the second half of 2025 [4] Cash Position - As of September 30, 2024, Vericel had approximately $151 million in cash, restricted cash, and investments, with no debt [8]